Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation. 
T he B-type natriuretic peptides (BNP and NT-proBNP) are elevated in patients with chronic heart failure (HF). [1] [2] [3] Recent reports suggest that what is being measured and reported clinically actually represents multiple peptide fragments. [4] [5] [6] It appears that ProBNP 1-108, the intact precursor peptide to BNP and NT-proBNP, circulates at high concentrations in patients with HF 7 and may be the predominant form of circulating natriuretic peptide. [8] [9] [10] In addition, it is clear now that breakdown products of BNP 1-32 circulate as well. 4, 5, [11] [12] [13] Thus, it appears that there is probably very little bioactive BNP moiety (BNP 1-32) in the plasma of HF patients. 14, 15 These findings in aggregate suggest abnormalities in the processing of proBNP 1-108. This problem along with the breakdown of the biologically most potent fragment (BNP 1-32) 12 may be a basis for the poor compensatory response of the NP system in chronic HF.
Clinical Perspective on p 360
Because there is substantial cross-reactivity of the commercially available BNP and NT-proBNP assays with proBNP, 14 the measured concentrations of these peptides are affected by the presence of the high circulating levels of proBNP that have been shown to have little biological activity. 4, 12 In addition, most of the degradation fragments of BNP 1-32 are also detected by BNP assays. 14 Determining the fragments that circulate in patients is complex. Many natriuretic peptide assay measurements are confounded by preanalytic issues such as the absence of an appropriate inhibition of the protease degradation process at the time of blood collection. 16 This degradation process alters the peptide forms within the collecting tube itself before assay of the analyte. Therefore, before making any definitive statements about which form or forms of BNP circulate in the plasma, preanalytic steps have to be undertaken to ensure that the blood samples are properly preserved. Recently, a proprietary drug "cocktail" has been developed (Ortho-Clinical Diagnostics, Raritan, NJ) that inhibits the proteolysis of BNP in plasma samples. Studies with plasma samples spiked with bioactive BNP have demonstrated complete inhibition of the degradation process. 11 Additionally, methods have been developed to evaluate fragments of BNP using mass spectrometry analysis that permit precise identification of the circulating forms of BNP present in the preserved samples. Accordingly, in this observational study, we used these techniques to analyze plasma specimens from patients with diagnosed chronic HF who presented to the Mayo Heart Failure Clinic for evaluation. The purpose of this study was to investigate the association of clinically available BNP values with the information on the fragments detected by mass spectrometry, and to provide quantitative data on which type of BNP fragments circulate in the plasma of patients with clinical HF. Such data will provide a more complete and accurate profile of the spectrum of natriuretic peptides that contribute to the neurohormonal response of chronic HF. To understand more about the processes involved, we also measured the putative major convertase enzyme for proBNP, corin, and the related peptide NT-proANP.
Methods
Blood samples were obtained under resting conditions in tubes containing protease inhibitor from 70 consecutive patients who provided written consent and were diagnosed with HF by Framingham criteria (systolic or diastolic) consistent with New York Heart Association (NYHA) Class I-IV during the period of March 31 to November 3, 2007. Patients were monitored for 12 months. One plasma aliquot was processed and frozen at Ϫ70°C for spectrometry analysis. Another aliquot was processed, frozen, and stored for batch analysis with standard clinical antibody assays currently available commercially and used in clinical medicine laboratories. All patients provided informed consent for the blood draw and storage of the plasma specimen and also utilization of their clinical information for this study. The study was approved by the Mayo Clinic Foundation Institutional Research Review Board and included only those patients who provided written consent as required by Minnesota Statute 144.335/CRF 21.
Protease inhibition and quantitative mass spectrometry immunoassay (MISA, Intrinsic Bioprobes, Hayward, CA) were used as previously reported. 11 This process used EDTA vacutainers and immediate processing. After centrifugation, the samples were transferred into storage tubes containing benzamidine and AEBSF (final inhibitor concentration 10 mmol/L and 5 mmol/L, respectively). This approach has been shown to inhibit protease processing of BNP fragments. 11 Clinical BNP 1-32 was measured by standard clinical laboratory assay techniques using the Beckman assay on the DXI analyzer. 17 ProBNP levels were determined at Ortho-Clinical Diagnostics (Raritan, NJ) using Hytest antibodies (Hytest 18H5, NT-proBNP). 10 The specifications of this assay indicate Ͻ1.5% cross-reactivity with BNP and NT-proBNP. N-Terminal proatrial natriuretic peptide 1-98 (NT-proANP) concentration was measured by immunoluminometric assay (NT-proANP LIA, ALPCO) on a Berthold LB952 Auto CliniLumat Luminescence. 18 Corin, a serine protease that enzymatically converts precursor peptide proBNP into BNP and NT-proBNP, was measured by a commercially available research human corin immunoassay (ELISA, Human corin DuoSet kit, R&D Systems, Minneapolis, MN). 19 
Statistical Analyses
Continuous variable data are reported as meanϮSD or median with minimum-maximum values for nonnormally distributed variables. 
Results
Patient demographics and clinical characteristics at study enrollment are shown in Table 1 . The majority of patients were male, in NYHA Class II-III HF with mild to moderate renal insufficiency, and on standard HF medical therapy. This is reflective of the typical HF patients followed in our outpatient HF clinic. At 12-month follow-up, 7 patients had died (10%). Table 2 provides a summary assessment of the natriuretic peptides measured in this patient cohort. ProBNP 1-108, corin, and clinically measured BNP 1-32 levels were elevated consistent with the diagnosis of HF. In contrast, mass spectrometry (MS) BNP 1-32 levels were low and differed significantly from the clinical BNP measurements (Pϭ0.01). The sum of MS BNP 1-32 and the MS fragments (3-32, 4-32, and 5-32) did not approximate the measured clinical BNP value. A mean of 2.7 fragments were present in each individual patient with approximately 1 of 3 of patients (25/70) demonstrating the presence of BNP 1-32 in addition to all the other fragments. Fragments 3-32, 4-32, and 5-32, respectively, demonstrated higher concentrations relative to the intact MS BNP 1-32 value. BNP fragments with mass corresponding to 2-31, 3-27, 3-39, 4-27, 4-30, 4-31, 5-31, 6-32 were also detected in some samples, but concentrations could not be determined and no clear trend was associated with any of these fragments. Therefore, these were not included in the analytes presented here. Table 3 Although there was a statistically significant inverse correlation with LVEF for a few of the MS fragments and clinically measured natriuretic peptides, the associations were at best modest. We also analyzed the associations of NYHA class (I-II and III-IV), etiology of HF (ischemic and nonischemic), quartiles of body mass index (Ͻ24, 25 to 27, 27 to 31, Ն32), and duration of HF with biomarker fragments. None of these demonstrated a statistically significant association other than NYHA class (Table 3 ). There were no detectable patterns related to outcomes from these data other than that 12-month nonsurvivors demonstrated higher clinical BNP levels relative to survivors (1935Ϯ1104 versus 583Ϯ620 pg/mL, PϽ0.05). 
Discussion
The findings of this study are consistent with and extend recent reports that suggest that there is very little of the biologically active BNP 1-32 in the circulation of patients with chronic HF. This is, to our knowledge, the largest cohort thus far reported describing the MS separation of these fragments. These data are to some extent at odds with the idea that proBNP 1-108 is the most common circulating form detected by the present iteration of BNP assays. Indeed, although proBNP 1-108 clearly contributed to the cumulative results of the BNP assay, there was a better correlation with degradation products of BNP 1-32 than with proBNP 1-108. Best data indicate that these various fragments are not nearly as effective in stimulating the beneficial effects of natriuretic peptides as BNP 1-32. 12 This may be because these fragments are eliminated more rapidly. Initial experiments with BNP 3-32 suggest that it stimulates the second messenger, cyclic GMP, quite well, but when infused, it had no effect. 12 Thus, some have suggested that inhibition of the cleavage of amino acids 1 and 2 by the use of dipeptidyl peptidase (DPPIV) inhibitors might be efficacious. 13 There are no data, however, to support this speculation, but our data do not contradict this suggestion. The data in regard to the 4-32 and 5-32 fragments are still evolving. 11, 13, 20, 21 It is clear that proBNP is fairly abundant and is measured by the BNP assay we used and also by a variety of others. 14 This may in part be because proBNP is not processed properly in patients with HF because glycosylation of amino acid 71 inhibits the effects of convertase. 22, 23 Thus, proper processing is inhibited and proBNP increases in blood. The mechanism for the presumed lack of deglycosylation is unclear. It should also be noted that glycosylation also plays a major role in mitigating the values of NT-proBNP perhaps by inhibiting the epitope binding sites needed for the assay. Thus, deglycosylation markedly increases values of NTproBNP. 23 Differential de-glycosylation also may explain why some patients have very high levels of NT-proBNP and others more modest levels. This is clearly area where more investigation is needed.
The fact that clinical BNP measurements reflect cumulative fragment values rather than intact BNP 1-32 also provides an explanation for why, despite the high levels of BNP measured by conventional assays, these potent peptides do not result in clinical compensation of HF. It appears that part of the pathogenesis of HF includes dysregulation of the natriuretic peptide system.
The observation that corin is not well correlated (negatively in this study) with other clinical and/or biochemical products suggests that its production or perhaps its effect in the face of glycosylation may be one of the abnormalities associated with HF. We were unable to measure furin, the other putative convertase for proBNP. 20 However, the abnormality does not appear to be in the production of proBNP 1-108, which seems to be produced in adequate quantities but is not processed appropriately to provide an effective biologically active peptide to function in a counterregulatory response to neurohormonally deranged chronic HF. The observation that clinically measured BNP 1-32 correlates best, albeit not robustly, with MS fragments (3-32, 4-32, and 5-32) and relatively poorly with MS BNP 1-32 suggests that a significant component of circulating clinical BNP 1-32 is composed of such fragments which would be expected to demonstrate little compensatory biological activity. ProBNP 1-108 correlated very poorly with MS BNP 1-32 (rϭ0.05) and only modestly with clinical BNP 1-32 (rϭ0.43, PϽ0.001). Thus, multiple pathways appear to be involved in the dysregulation seen in patients with HF.
No particular pattern of biomarkers appeared to have prognostic importance from our data other than elevated clinical BNP 1-32 being higher in 12-month nonsurvivors relative to survivors. This may simply be because of the complexity of the biochemical abnormalities or the relatively small patient numbers of our study. However, if we could understand the nature of these perturbations, we might be able to inhibit some of the pathological processes that lead to dysfunction of the natriuretic system in HF patients. Additionally, there may be some patterns that can with time be identified that would be amenable to therapeutic manipulation. Additional investigation is clearly needed.
Limitations of the Study
These data were obtained for a cohort of outpatients with chronic and stable HF. It is unclear whether similar abnormalities should be expected in patients with more acute HF presentations. In addition, although our data are extensive compared with most in the literature, they still reflect a small number of patients.
Conclusions
These data begin to provide the basis for studies to understand and thus to provide insights into how to inhibit some of the processes related to the dysregulation of the NP system in patients with HF. Both the processing of proBNP by its convertases and the downstream degradation of BNP 1-32 appear to be critical.
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